PMID- 26999201
OWN - NLM
STAT- MEDLINE
DCOM- 20161213
LR  - 20181202
IS  - 2072-6651 (Electronic)
IS  - 2072-6651 (Linking)
VI  - 8
IP  - 3
DP  - 2016 Mar 16
TI  - Adverse Events of Intravesical OnabotulinumtoxinA Injection between Patients with 
      Overactive Bladder and Interstitial Cystitis--Different Mechanisms of Action of 
      Botox on Bladder Dysfunction?
LID - 10.3390/toxins8030075 [doi]
LID - 75
AB  - Intravesical onabotulinumtoxinA (BoNT-A) injections have been proposed to treat 
      both overactive bladder (OAB) and interstitial cystitis/bladder pain syndrome 
      (IC/BPS) in patients with refractory conditions. We compared adverse events (AEs) 
      after BoNT-A treatment between IC/BPS and OAB in women. IC/BPS patients who 
      failed conventional treatments were enrolled to receive suburothelial injections 
      of BoNT-A (100 U) followed by hydrodistention. Age matched OAB female patients 
      refractory to antimuscarinic agents underwent BoNT-A (100 U) injections. The 
      bladder capacity, maximum flow rate (Qmax), post-void residual (PVR), and voiding 
      efficiency (VE) at baseline, 3 and 6 months, and the post-treatment AEs were 
      analyzed between groups. Finally, 89 IC/BPS and 72 OAB women were included. In 
      the OAB group, the bladder capacity and PVR increased, and VE decreased 
      significantly at three and six months after BoNT-A treatment. In the IC/BPS 
      group, the Qmax increased significantly at six months. There were significant 
      differences in changes of capacity, Qmax, PVR and VE between the two groups. 
      Moreover, OAB patients suffered more frequently from events of hematuria, UTI, 
      and large PVR (>200 mL), but less frequently from events of straining to void. In 
      conclusion, OAB women had higher PVR volume and lower VE than those in IC/BPS 
      after BoNT-A injections. These results imply that the bladder contractility of 
      OAB patients are more susceptible to BoNT-A, which might reflect the different 
      mechanisms of action of Botox on bladder dysfunction. Further investigations to 
      confirm this hypothesis are warranted.
FAU - Kuo, Yuh-Chen
AU  - Kuo YC
AD  - Department of Urology, Yangming Branch of Taipei City Hospital, Taipei 11146, 
      Taiwan. yuhchens@hotmail.com.
AD  - Department of Urology, Buddhist Tzu Chi General Hospital and Tzu Chi University, 
      Taipei 11146, Taiwan. yuhchens@hotmail.com.
FAU - Kuo, Hann-Chorng
AU  - Kuo HC
AD  - Department of Urology, Buddhist Tzu Chi General Hospital and Tzu Chi University, 
      Taipei 11146, Taiwan. hck@tzuchi.com.tw.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20160316
PL  - Switzerland
TA  - Toxins (Basel)
JT  - Toxins
JID - 101530765
RN  - EC 3.4.24.69 (Botulinum Toxins, Type A)
SB  - IM
MH  - Administration, Intravesical
MH  - Adult
MH  - Botulinum Toxins, Type A/administration & dosage/*adverse effects/therapeutic use
MH  - Cystitis, Interstitial/*drug therapy/physiopathology
MH  - Female
MH  - Humans
MH  - Middle Aged
MH  - Urinary Bladder, Overactive/*drug therapy/physiopathology
PMC - PMC4810220
OTO - NOTNLM
OT  - adverse events
OT  - interstitial cystitis
OT  - onabotulinumtoxinA
OT  - overactive bladder
EDAT- 2016/03/22 06:00
MHDA- 2016/12/15 06:00
PMCR- 2016/03/01
CRDT- 2016/03/22 06:00
PHST- 2016/01/17 00:00 [received]
PHST- 2016/02/29 00:00 [revised]
PHST- 2016/03/07 00:00 [accepted]
PHST- 2016/03/22 06:00 [entrez]
PHST- 2016/03/22 06:00 [pubmed]
PHST- 2016/12/15 06:00 [medline]
PHST- 2016/03/01 00:00 [pmc-release]
AID - toxins8030075 [pii]
AID - toxins-08-00075 [pii]
AID - 10.3390/toxins8030075 [doi]
PST - epublish
SO  - Toxins (Basel). 2016 Mar 16;8(3):75. doi: 10.3390/toxins8030075.